Under certain conditions, Canadian and international accounting standards allow firms to present R&D costs in their balance sheets (capitalization). This article analyzes the determinants of new capitalizations of R&D costs by focusing on positive accounting theory and the influence of the CEO. Based on a sample of 440 observations of Canadian firms between the years 2000 and 2003, the results show that the size, debt load, presence of a CEO who holds an important but not majority block of shares, and CEO’s years of seniority all influence the decision to present new capitalizations of R&D costs. The presence on the board of an important stockholder other than the CEO attenuates the influence of the CEO.